Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93139ArticlesСтатьиResearch ArticleSovremennye vozmozhnosti blokady renin-angiotenzinovoy sistemy: ostayutsya li ingibitory angiotenzinprevrashchayushchego fermenta preparatami pervogo ryada?Современные возможности блокады ренин-ангиотензиновой системы: остаются ли ингибиторы ангиотензинпревращающего фермента препаратами первого ряда?GilyarevskiyS. RГиляревскийС. РНИИ скорой помощи им. Н.В.Склифосовского, Москва15052010125VOL 12, NO5 (2010)ТОМ 12, №5 (2010)182328122021Copyright ©; 2010, Consilium MedicumCopyright ©; 2010, ООО "Консилиум Медикум"2010Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93139

Имеются данные о том, что активация ренин-ангиотензин-альдостероновой системы (РААС) играет важную роль в развитии заболеваний сердца и сосудов, а подавление активности и/или блокада такой системы приводит к снижению частоты развития осложнений сердечно-сосудистых заболеваний (ССЗ) и смертности от них [1]. Однако до настоящего времени нет однозначного мнения по поводу оптимального подхода к подавлению активности РААС. Результаты исследований ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) [2], TRANSCEND (Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease) [3], а также исследования NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) [4], включавшие больных с высоким риском развития осложнений сосудистых заболеваний, предоставили достаточно надежные основания для определения обосновании подавления РААС. Тем не менее сложившееся представление о тактике воздействия на РААС продолжает изменяться в связи с появлением новых данных. Несмотря на интенсивное изучение РААС в ходе выполнения доклинических и клинических исследований, отсутствует полное представление о последствиях активации РААС и оптимальных подходах к предупреждению ее последствий

Pitt B. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large - scale randomised trials for clinical practice. Heart 2009; 95: 1205–8.The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–59.The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin - receptor blocker telmisartan on cardiovascular events in high - risk patients intolerant to angiotensin - converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–83.The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010; 362: 1477–90.Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8.Braunwald E, Domanski M.J, Fowler S.E et al. Angiotensin - converting -enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.Pitt B, O\'Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058–63.Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9.Cohn J.N, Tognoni G. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75.Pfeffer M.A, Mc Murray J.J, Velazquez E. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.Pitt B, Poole - Wilson P.A, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high - risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752–60.Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin - converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta - analysis. J Hypertens 2008; 26: 1282–9.Yusuf S, Diener H.C, Sacco R.L et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225–37.Mc Murray J.J.V. ACE Inhibitors in Cardiovascular Disease – Unbeatable? N Engl J Med 2008; 358(15): 1615–6.Mc Murray J.J, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function taking angiotensin - converting - enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71.Cruden .NL, Witherow F.N, Webb D.J et al. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin - converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 2004; 24: 1043–8.Gohlke P, Kuwer I, Schnell A et al. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensinconverting enzyme inhibitor treatment in stroke - prone spontaneously hypertensive rats. Hypertension 1997; 29(Pt 2): 478–2.Akinboboye O.O, Chou R.L, Bergmann S.R. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. J Am Coll Cardiol 2002; 40: 703–9.Buus N.H, Bottcher M, Jorgensen C.G et al. Myocardial perfusion during long - term angiotensinconverting enzyme inhibition or beta - blockade in patients with essential hypertension. Hypertension 2004; 44: 465–70.Turnbull F, Neal B, Pfeffer M et al. Blood pressure - dependent and independent effects of agents that inhibit the renin - angiotensin system. J Hypertens 2007; 25: 951–8.Krankel N, Katare R.G, Siragusa M et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res 2008; 103: 1335–43.Ilanne-Parikka P, Eriksson J.G, Lindstro.m J et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care 2008; 31: 805–7.Li G, Zhang P, Wang J et al. The long - term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow - up study. Lancet 2008; 371: 1783–9.Mann J.F, Schmieder R.E, Mc Queen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double - blind, controlled trial. Lancet 2008; 372: 547–53.Shibata M.C, Tsuyuki R.T, Wiebe N. The effects of angiotensin - receptor blockers on mortality and morbidity in heart failure: a systematic review. Int J Clin Pract 2008; 62: 1397–402.Phillips C.O, Kashani A, Ko D.K et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin - converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930–6.Matchar D.B, Mc Crory D.C, Orlando L.A et al. Systematic review: comparative effectiveness of angiotensin - converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16–29.Kunz R, Friedrich C, Wolbers M et al. Meta - analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48.Krum H, Carson P, Farsang C et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val - HeFT. Eur J Heart Fail 2004; 6: 937–45.Mc Murray J.J, Young J.B, Dunlap M.E et al. Relationship of dose of background angiotensin - converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J2006; 151: 985–91.Lakhdar R, Al-Mallah M.H, Lanfear D.E. Safety and tolerability of angiotensin - converting enzyme inhibitor versus the combination of angiotensin - converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta - analysis of randomized controlled trials. J Card Fail 2008; 14: 181–8.Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–17.Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21.Montezano A.C, Callera G.E, Yogi A et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c - Src - regulated redox - sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511–8.Calhoun D, Nishizaka M, Zaman M et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892–6.Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839–45.Stas S, Whaley-Connell A.T, Sowers J.R. Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008; 10: 94–6.Pitt B, Bakris G, Ruilope L.M et al. Serum potassium and clinical outcomes in the Eplerenone Post - Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643–50.Imanishi T, Tsujioka H, Ikejima H et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52: 563–72.McMurray J, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17–24.Pitt B, Mc Murray J, Latifi R et al. Heart failure: neurohormonal modulation [abstract]. Circulation 2007; 116: 2491.Fisher N.D, Hollenberg N.K. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592–9.Stiles S. ASPIRE: Adding aliskiren to post - MI meds won\'t help ventricular function. Available at: www.theheart.org. March 23, 2010.O\'Riordan M. Limited new indication for telmisartan a reasonable choice given the data, says FDA panel. Available at: theheart.org July 30, 2009Fiebeler A, Nussberger J, Shagdarsuren E et al. Aldosterone synthase inhibitor ameliorates angiotensin II - induced organ damage. Circulation 2005; 111: 3087–94.Kaschina E, Grzesiak A, Li J et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin - angiotensin system in myocardial infarction? Circulation 2008; 118: 2523–2.Mercure C, Yogi A, Callera G.E et al. Angiotensin(1–7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103: 1319–26.Tissot A.C, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006 - AngQb on ambulatory blood pressure: a double - blind, randomised, placebo - controlled phase IIa study. Lancet 2008; 371: 821–7.